The McGill Antimicrobial Resistance (AMR) Centre is partnering with the McGill Innovation Fund (MIF) to provide an exciting new funding opportunity to support the commercialization of research. The MIF is one of the largest entrepreneurial funding programs in the University and has already supported nearly 20 teams since its inception.
The new MIF-AMR Award would offer additional funding to teams who already secured funding in the regular MIF streams: Discover ($25,000), Develop ($50,000) and Deploy ($100,000). Successful teams will be chosen for their potential to prevent, diagnose and treat life-threatening bacterial infections. The total amount of funding available for the MIF-AMR Award is $75,000, which will be distributed at the discretion of the judging panel.
To be eligible to apply to the MIF requires an approved Report of Invention, as designated by the Office of Innovation + Partnerships. Companies who have a signed license agreement with McGill University are also eligible. Full details of the award and application process are available at mcgill.ca/mif
Winners of the MIF-AMR 2024 Awards
We were excited to welcome the two MIF-AMR winning teams at the MIF’s Passing the Torch event on February 1, 2024. The team “Itaconate Antibiotic” led by Profs. Karine Auclair (McGill University) and Andréanne Lupien (RI MUHC) received the Discovery MIF and MIF-AMR award ($25K + $25K), and the team “Patholyzer” led by Prof. Parisa Ariya (McGill University) received the Develop MIF and MIF-AMR ($50K + $50K). We look forward to following the success of these teams through the MIF program.